Entera Bio grants RSUs to Chief of R&D

Burshtein Gregory reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Burshtein Gregory reported acquisition or exercise transactions in this Form 4 filing.

Entera Bio Ltd. reported that its Chief of R&D, Gregory Burshtein, received an equity grant rather than cash. He was awarded 87,591 ordinary shares in the form of stock-settled restricted stock units, approved by the Board on May 7, 2026, in lieu of a cash bonus.

The restricted stock units vest ratably on a quarterly basis over one year, beginning May 1, 2026. After this grant, Burshtein directly owns 189,033 ordinary shares, reflecting routine, compensation-related equity that does not involve any open-market buying or selling.

Insider Trade Summary

Grant/Award: 87,591 shares

Grant/Award 1 txn

Insider Burshtein Gregory

Role Chief of R&D

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares, par value NIS 0.0000769 per share	87,591	$0.00	$0.00

Holdings After Transaction: Ordinary Shares, par value NIS 0.0000769 per share — 189,033 shares (Direct)

Footnotes (1)

1. F1. Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026. This grant was awarded to the Reporting Person in lieu of a cash bonus the Reported Person was otherwise entitled to. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026.

Key Figures

RSUs granted: 87,591 shares Shares owned after grant: 189,033 shares Vesting schedule length: 1 year +3 more

6 metrics

RSUs granted 87,591 shares Stock-settled restricted stock units granted in lieu of cash bonus

Shares owned after grant 189,033 shares Total ordinary shares directly owned by Burshtein after transaction

Vesting schedule length 1 year Restricted stock units vest ratably on a quarterly basis

Vesting start date May 1, 2026 Beginning of quarterly vesting period for RSUs

Board approval date May 7, 2026 Date Board of Directors approved the restricted stock unit grant

Transaction price per share $0.0000 Form 4 shows no cash price for the RSU grant

Key Terms

restricted stock units, stock-settled, Board of Directors, cash bonus, +1 more

5 terms

restricted stock units financial

"Represent a grant of stock-settled restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

stock-settled financial

"Represent a grant of stock-settled restricted stock units."

Board of Directors financial

"This grant ... was approved by the Board of Directors (the "Board")"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

cash bonus financial

"awarded to the Reporting Person in lieu of a cash bonus"

vest ratably financial

"The restricted stock units vest ratably on a quarterly basis"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Entera Bio (ENTX) report for Gregory Burshtein?

Entera Bio reported an equity grant to Chief of R&D Gregory Burshtein. He received 87,591 stock-settled restricted stock units as compensation. The award replaced a cash bonus and increases his direct holdings to 189,033 ordinary shares, without any open-market share purchases or sales.

How many Entera Bio (ENTX) shares were granted to the Chief of R&D?

Gregory Burshtein was granted 87,591 ordinary shares in the form of stock-settled restricted stock units. These units were awarded instead of a cash bonus and vest over one year, adding to his overall direct ownership position in Entera Bio Ltd.

How do the Entera Bio (ENTX) restricted stock units vest for the Chief of R&D?

The restricted stock units vest quarterly over one year, starting May 1, 2026. This means a portion of the 87,591 stock-settled units becomes share-deliverable each quarter, aligning Burshtein’s compensation more closely with Entera Bio’s share performance during that period.

Was the Entera Bio (ENTX) grant to Gregory Burshtein a cash transaction?

No, the grant replaced a cash bonus. The Board approved stock-settled restricted stock units instead of paying a cash bonus Burshtein was otherwise entitled to. This shifts compensation into equity, but does not involve any open-market cash purchase or sale of shares.

What is Gregory Burshtein’s total Entera Bio (ENTX) shareholding after the grant?

After the grant, Burshtein directly owns 189,033 ordinary shares of Entera Bio Ltd. This total reflects the addition of 87,591 stock-settled restricted stock units awarded as compensation, recorded as an acquisition rather than a market trade in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/08/2026 - 04:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burshtein Gregory

(Last) (First) (Middle)

KIRYAT HADASSAH, MINRAV BUILDING,

FIFTH FLOOR

(Street)

JERUSALEM 9112002

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Entera Bio Ltd. [ ENTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief of R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares, par value NIS 0.0000769 per share	05/07/2026		A		87,591	A	$0(1)	189,033	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026. This grant was awarded to the Reporting Person in lieu of a cash bonus the Reported Person was otherwise entitled to. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026.

	/s/ Dana Yaacov-Garbeli, Attorney-in-fact	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)